Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants

Jonsson Comprehensive Cancer Center3 enrolled

Overview

RATIONALE: Fluorine F 18 FEQA may be an effective radioactive drug to use with positron emission tomography (PET) scans. PURPOSE: This clinical trial is studying the use of fluorine F 18 FEQA in patients with stage III or stage IV non-small cell lung cancer and in healthy participants.

OBJECTIVES: * Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV non-small cell lung cancer (NSCLC) and in healthy participants. * Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron emission tomography in patients with stage III or IV NSCLC. OUTLINE: This is a pilot study. Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body dynamic scans comprising positron emission tomography. Blood is collected during and after imaging to measure radioactivity. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Lung Cancer

Interventions

fluorine F 18 FEQA + positron emission tomographyPROCEDURE

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Must meet 1 of the following criteria: * Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy * Stage III or IV disease * Clinically assessed with * Healthy participant Exclusion Criteria:

Locations (1)

Jonsson Comprehensive Cancer Center at UCLA

Los Angeles, California, United States

Outcomes

Primary Outcomes

Biodistribution of fluorine F 18 FEQA

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.